Message From the Editor-in-Chief
The Circulation Journal Official Impact Factor and the Most Frequently Cited Papers in 2020
2022 Volume 86 Issue 1 Pages 2-5
Details
2022 Volume 86 Issue 1 Pages 2-5
Dear Colleagues,
On behalf of the Circulation Journal, I would like to report its official 2020 Impact Factor and the related information in detail as follows:
I would like to report that Circulation Journal has earned an official 2020 Impact Factor of 2.993 (2019: 2.540). The official ranking places Circulation Journal the 74th among the 138 journals in the Cardiac & Cardiovascular Systems category in 2020 JCR Science Edition (64th among the 138 journals in 2019). I would like to ask readers to use Circulation Journal papers as reference papers in your future submission of manuscripts to any journals.
The following papers, published in 2018–2019, were among the top 34 most frequently cited papers in 2020, thereby substantially contributing to the 2020 Impact Factor of the Journal (number in the parenthesis denoted the number of citations in 2018–2019).
1. (37) Kimura K, Kimura T, Ishihara M, Nakagawa Y, Nakao K, Miyauchi K, et al; JCS Joint Working Group. JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome. Circ J 2019; 83: 1085–1196.
2. (35) Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, et al; JCS and JHFS Joint Working Group. JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure: Digest version. Circ J 2019; 83: 2084–2184.
3. (20) Abe Y, Akamatsu K, Ito K, Matsumura Y, Shimeno K, Naruko T, et al. Prevalence and prognostic significance of functional mitral and tricuspid regurgitation despite preserved left ventricular ejection fraction in atrial fibrillation patients. Circ J 2018; 82: 1451–1458.
(20) Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, Oiwa K, et al; for the SAKURA AF Registry Investigators. Three-year clinical outcomes associated with warfarin vs. direct oral anticoagulant use among Japanese patients with atrial fibrillation: Findings from the SAKURA AF registry. Circ J 2018; 82: 2500–2509.
5. (18) Anzai T. Inflammatory mechanisms of cardiovascular remodeling. Circ J 2018; 82: 629–635.
6. (17) Nagai T, Yoshikawa T, Saito Y, Takeishi Y, Yamamoto K, Ogawa H, et al; on behalf of the JASPER Investigators. Clinical characteristics, management, and outcomes of Japanese patients hospitalized for heart failure with preserved ejection fraction: A report from the Japanese heart failure syndrome with preserved ejection fraction (JASPER) registry. Circ J 2018; 82: 1534–1545.
7. (16) Nakatani S, Ohara T, Ashihara K, Izumi C, Iwanaga S, Eishi K, et al; JCS Joint Working Group. JCS 2017 guideline on prevention and treatment of infective endocarditis. Circ J 2019; 83: 1767–1809.
8. (15) Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, Kim K, et al; on behalf of COMMAND VTE Registry Investigators. Anticoagulation therapy for venous thromboembolism in the real world: From the COMMAND VTE registry. Circ J 2018; 82: 1262–1270.
(15) Yaku H, Ozasa N, Morimoto T, Inuzuka Y, Tamaki Y, Yamamoto E, et al; on behalf of the KCHF Study Investigators. Demographics, management, and in-hospital outcome of hospitalized acute heart failure syndrome patients in contemporary real clinical practice in Japan. Circ J 2018; 82: 2811–2819.
10. (14) Fukuda K, Date H, Doi S, Fukumoto Y, Fukushima N, Hatano M, et al; JCS and JPCPHS Joint Working Group. Guidelines for the treatment of pulmonary hypertension (JCS 2017/JPCPHS 2017). Circ J 2019; 83: 842–945.
11. (13) Motoyama S, Ito H, Sarai M, Nagahara Y, Miyajima K, Matsumoto R, et al. Ultra-high-resolution computed tomography angiography for assessment of coronary artery stenosis. Circ J 2018; 82: 1844–1851.
12. (11) Nagao K, Taniguchi T, Morimoto T, Shiomi H, Ando K, Kanamori N, et al; on behalf of the CURRENT AS Registry Investigators. Acute heart failure in patients with severe aortic stenosis: Insights from the CURRENT AS registry. Circ J 2018; 82: 874–885.
(11) Tada H, Okada H, Nomura A, Yashiro S, Nohara A, Ishigaki Y, et al. Rare and deleterious mutations in ABCG5/ABCG8 genes contribute to mimicking and worsening of familial hypercholesterolemia phenotype. Circ J 2019; 83: 1917–1924.
(11) De Rosa R, Silverio A, Baldi C, Di Maio M, Prota C, Radano I, et al. Transcatheter repair of functional mitral regurgitation in heart failure patients: A meta-analysis of 23 studies on mitraClip implantation. Circ J 2018; 82: 2800–2810.
(11) Nagar SP, Rane PP, Fox KM, Meyers J, Davis K, Beaubrun A, et al. Treatment patterns, statin intolerance, and subsequent cardiovascular events among japanese patients with high cardiovascular risk initiating statin therapy. Circ J 2018; 82: 1008–1016.
(11) Kondo K, Yanishi K, Hayashida R, Shintani S, Shibata R, Murotani K, et al; TACT Follow-up Study Investigators. Long-term clinical outcomes survey of bone marrow-derived cell therapy in critical limb ischemia in Japan. Circ J 2018; 82: 1168–1178.
17. (10) Terasaki F, Azuma A, Anzai T, Ishizaka N, Ishida Y, Isobe M, et al; JCS Joint Working Group. JCS 2016 guideline on diagnosis and treatment of cardiac sarcoidosis: Digest version. Circ J 2019; 83: 2329–2388.
(10) Inomata T, Ikeda Y, Kida K, Shibagaki Y, Sato N, Kumagai Y, et al; for the Kanagawa Aquaresis Investigators. Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment: Results from the K-STAR study. Circ J 2018; 82: 159–167.
(10) Tamura Y, Kumamaru H, Satoh T, Miyata H, Ogawa A, Tanabe N, et al; on behalf of the Japan PH Registry (JAPHR) Network. Effectiveness and outcome of pulmonary arterial hypertension-specific therapy in japanese patients with pulmonary arterial hypertension. Circ J 2018; 82: 275–282.
(10) Murata N, Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, et al; for the SAKURA AF Registry Investigators. Clinical outcomes of off-label dosing of direct oral anticoagulant therapy among japanese patients with atrial fibrillation identified from the SAKURA AF registry. Circ J 2019; 83: 727–735.
(10) Hayashi T, Yamashita T, Watanabe H, Kami K, Yoshida N, Tabata T, et al. Gut microbiome and plasma microbiome-related metabolites in patients with decompensated and compensated heart failure. Circ J 2019; 83: 182–192.
(10) Yoshimura S, Koga M, Sato S, Todo K, Yamagami H, Kumamoto M, et al; for the SAMURAI Study Investigators. Two-year outcomes of anticoagulation for acute ischemic stroke with nonvalvular atrial fibrillation: SAMURAI-NVAF study. Circ J 2018; 82: 1935–1942.
(10) Hayashi K, Tsuda T, Nomura A, Fujino N, Nohara A, Sakata K, et al; on behalf of the Hokuriku-Plus AF Registry Investigators. Impact of b-type natriuretic peptide level on risk stratification of thromboembolism and death in patients with nonvalvular atrial fibrillation: The hokuriku-plus AF registry. Circ J 2018; 82: 1271–1278.
(10) Sano S, Wang Y, Walsh K. Clonal hematopoiesis and its impact on cardiovascular disease. Circ J 2019; 83: 2–11.
(10) Iguchi M, Tezuka Y, Ogawa H, Hamatani Y, Takagi D, An Y, et al. Incidence and risk factors of stroke or systemic embolism in patients with atrial fibrillation and heart failure: The fushimi AF registry. Circ J 2018; 82: 1327–1335.
(10) Sakamoto J, Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, et al; on behalf of the COMMAND VTE Registry Investigators. Cancer-associated venous thromboembolism in the real world: From the COMMAND VTE registry. Circ J 2019; 83: 2271–2281.
(10) Nakashima T, Noguchi T, Tahara Y, Nishimura K, Ogata S, Yasuda S, et al; for the SAVE-J Group. Patients with refractory out-of-cardiac arrest and sustained ventricular fibrillation as candidates for extracorporeal cardiopulmonary resuscitation: Prospective multi-center observational study. Circ J 2019; 83: 1011–1018.
28. (9) Yokoyama M, Watanabe T, Otaki Y, Watanabe K, Toshima T, Sugai T, et al. Impact of objective malnutrition status on the clinical outcomes in patients with peripheral artery disease following endovascular therapy. Circ J 2018; 82: 847–856.
(9) Lee CH, Cheng CL, Kao Yang YH, Chao TH, Chen JY, Li YH. Cardiovascular and bleeding risks in acute myocardial infarction newly treated with ticagrelor vs. clopidogrel in Taiwan. Circ J 2018; 82: 747–756.
(9) Tanaka T, Nishigaki K, Minatoguchi S, Nawa T, Yamada Y, Kanamori H, et al. Mobilized muse cells after acute myocardial infarction predict cardiac function and remodeling in the chronic phase. Circ J 2018; 82: 561–571.
(9) Kusunose K, Haga A, Abe T, Sata M. Utilization of artificial intelligence in echocardiography. Circ J 2019; 83: 1623–1629.
(9) Imamura T, Kinugawa K, Uriel N. Therapeutic strategy for gastrointestinal bleeding in patients with left ventricular assist device. Circ J 2018; 82: 2931–2938.
(9) Tsutsui H, Momomura S, Yamashina A, Shimokawa H, Kihara Y, Saito Y, et al; on behalf of the J-SHIFT Study Investigators. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure: J-SHIFT study. Circ J 2019; 83: 2049–2060.
(9) Heeger CH, Phan HL, Meyer-Saraei R, Fink T, Sciacca V, Liosis S, et al. Second-generation visually guided laser balloon ablation system for pulmonary vein isolation: Learning curve, safety and efficacy: The MERLIN registry. Circ J 2019; 83: 2443–2451.
The following papers, the 21,367 papers published in the Japanese Circulation Journal (1968–2001) and Circulation Journal (2002–2020), were among the top 38 most frequently cited papers (numbers in the parenthesis denote the number of citations).
1. (1121) Matsuzawa Y, Nakamura T, Takahashi M, Ryo M, Inoue S, Ikeda Y, et al. New criteria for ‘obesity disease’ in Japan. Circ J 2002; 66: 987–992. (Review)
2. (517) Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004; 68: 975–981.
3. (496) Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: Transition from theory to practice. Circ J 2010; 74: 213–220. (Review)
4. (445) Higashi Y, Noma K, Yoshizumi M, Kihara Y. Endothelial function and oxidative stress in cardiovascular diseases. Circ J 2009; 73: 411–418. (Review)
5. (385) Zhou Q, Liao JK. Pleiotropic effects of statins: Basic research and clinical perspectives. Circ J 2010; 74: 818–826. (Review)
6. (370) Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al; on behalf of the J-ROCKET AF study investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation: The J-ROCKET AF Study. Circ J 2012; 76: 2104–2111.
7. (325) Lee HY, Oh BH. Aging and arterial stiffness. Circ J 2010; 74: 2257–2262. (Review)
8. (307) Vanhoutte PM. Endothelial dysfunction: The first step toward coronary arteriosclerosis. Circ J 2009; 73: 595–601. (Review)
9. (278) Kitabatake A, Inoue M, Asao M, Tanouchi J, Masuyama T, Abe H, et al. Transmitral blood flow reflecting diastolic behavior of the left ventricle in health and disease: A study by pulsed Doppler technique. Jpn Circ J 1982; 46: 92–102.
10. (265) Inoue H, Atarashi H, Kamakura S, Koretsune Y, Kumagai K, Mitamura H, et al; JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013): Digest version. Circ J 2014; 78: 1997–2021.
11. (247) Jeong JW, Jeong MH, Yun KH, Oh SK, Park EM, Kim YK, et al. Echocardiographic epicardial fat thickness and coronary artery disease. Circ J 2007; 71: 536–539.
12. (245) Yoo TW, Sung KC, Shin HS, Kim BJ, Kim BS, Kang JH, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 2005; 69: 928–933.
13. (242) Hamano K, Nishida M, Hirata K, Mikamo A, Li TS, Harada M, et al. Local implantation of autologous bone marrow cells for therapeutic angiogenesis in patients with ischemic heart disease: Clinical trial and preliminary results. Jpn Circ J 2001; 65: 845–847.
14. (230) Kawai S, Suzuki H, Yamaguchi H, Tanaka K, Sawada H, Aizawa T, et al. Ampulla cardiomyopathy (‘Takotusbo’ cardiomyopathy): Reversible left ventricular dysfunction with ST segment elevation. Jpn Circ J 2000; 64: 156–159.
15. (222) Ando J, Yamamoto K. Vascular mechanobiology: Endothelial cell responses to fluid shear stress. Circ J 2009; 73: 1983–1992. (Review)
16. (220) Ueyama T, Kasamatsu K, Hano T, Yamamoto K, Tsuruo Y, Nishio I. Emotional stress induces transient left ventricular hypocontraction in the rat via activation of cardiac adrenoceptors: A possible animal model of ‘Takotsubo’ cardiomyopathy. Circ J 2002; 66: 712–713.
17. (203) Fujita K, Nishizawa H, Funahashi T, Shimomura I, Shimabukuro M. Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. Circ J 2006; 70: 1437–1442.
18. (195) Tomiyama H, Yamashina A. Non-invasive vascular function tests: Their pathophysiological background and clinical application. Circ J 2010; 74: 24–33. (Review)
(195) Kawai S, Kitabatake A, Tomoike H; Takotsubo Cardiomyopathy Study Group. Guidelines for diagnosis of Takotsubo (ampulla) cardiomyopathy. Circ J 2007; 71: 990–992.
20. (189) Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, Yokota T, Goto D, Yokoshiki H, et al; for the JCARE-CARD Investigators. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction: A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 1893–1900.
21. (185) Ogura R, Hiasa Y, Takahashi T, Yamaguchi K, Fujiwara K, Ohara Y, et al. Specific findings of the standard 12-lead ECG in patients with ‘Takotsubo’ cardiomyopathy: Comparison with the findings of acute anterior myocardial infarction. Circ J 2003; 67: 687–690.
22. (184) Swift DL, Lavie CJ, Johannsen NM, Arena R, Earnest CP, O’Keefe JH, et al. Physical activity, cardiorespiratory fitness, and exercise training in primary and secondary coronary prevention. Circ J 2013; 77: 281–292. (Review)
23. (180) Tomiyama H, Koji Y, Yambe M, Shiina K, Motobe K, Yamada J, et al. Brachial-ankle pulse wave velocity is a simple and independent predictor of prognosis in patients with acute coronary syndrome. Circ J 2005; 69: 815–822.
24. (178) Nakamura K, Tomaru T, Yamamura S, Miyashita Y, Shirai K, Noike H. Cardio-ankle vascular index is a candidate predictor of coronary atherosclerosis. Circ J 2008; 72: 598–604.
25. (174) Curcio A, Torella D, Indolfi C. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: Approach to therapy. Circ J 2011; 75: 1287–1296. (Review)
(174) Ehara M, Surmely JF, Kawai M, Katoh O, Matsubara T, Terashima M, et al. Diagnostic accuracy of 64-slice computed tomography for detecting angiographically significant coronary artery stenosis in an unselected consecutive patient population: Comparison with conventional invasive angiography. Circ J 2006; 70: 564–571.
27. (172) Shokawa T, Imazu M, Yamamoto H, Toyofuku M, Tasaki N, Okimoto T, et al. Pulse wave velocity predicts cardiovascular mortality: Findings from the Hawaii-Los Angeles-Hiroshima study. Circ J 2005; 69: 259–264.
28. (170) Ogawa H, Akasaka T, Hattori R, Inoue T, Kawashima S, Kawasuji M, et al; JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2013): Digest version. Circ J 2014; 78: 2779–2801.
29. (169) Sugimura K, Fukumoto Y, Satoh K, Nochioka K, Miura Y, Aoki T, et al. Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J 2012; 76: 485–488.
(169) Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ J 2010; 74: 597–607. (Review)
(169) Matsuzaki M, Kita T, Mabuchi H, Matsuzawa Y, Nakaya N, Oikawa S, et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia: Primary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J 2002; 66: 1087–1095.
32. (166) Takigiku K, Takeuchi M, Izumi C, Yuda S, Sakata K, Ohte N, et al. Normal range of left ventricular 2-dimensional strain: Japanese ultrasound speckle tracking of the left ventricle (JUSTICE) study. Circ J 2012; 76: 2623–2632.
33. (164) Harada M, Van Wagoner DR, Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. Circ J 2015; 79: 495–502. (Review)
34. (162) Ogawa H, Akasaka T, Hattori R, Kawashima S, Kawasuji M, Kimura K, et al; JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2008): Digest version. Circ J 2010; 74: 1745–1762.
35. (160) Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. Circ J 2014; 78: 1684–1692.
36. (156) Elrod JW, Molkentin JD. Physiologic functions of cyclophilin D and the mitochondrial permeability transition pore. Circ J 2013; 77: 1111–1122. (Review)
(156) Kurisu S, Inoue I, Kawagoe T, Ishihara M, Shimatani Y, Nakamura S, et al. Time course of electrocardiographic changes in patients with Tako-tsubo syndrome: Comparison with acute myocardial infarction with minimal enzymatic release. Circ J 2004; 68: 77–81.
(156) Ueshima H, Kasagi F, Kodama K, Okamura T, Hayakawa T, Okayama A, et al. Risk assessment chart for death from cardiovascular disease based on a 19-year follow-up study of a Japanese representative population: NIPPON DATA80. Circ J 2006; 70: 1249–1255.
The Editorial Team looks forward to receiving manuscripts with high scientific impact from all over the world.
